US · ALGN
Align Technology, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Tempe, AZ 85281
- Website
- aligntech.com
Price · as of 2025-12-31
$178.91
Market cap 13.64B
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $191.59 | +7.09% |
| Intrinsic Value(DCF) | $90.73 | -49.29% |
| Graham-Dodd Method(GD) | $77.32 | -56.78% |
| Graham Formula(GF) | $50.32 | -71.87% |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $26.60 | $53.90 | $106.03 | $8.83 | $26.59 |
| 2012 | $33.29 | $56.83 | $151.11 | $9.63 | $17.64 |
| 2013 | $55.28 | $63.73 | $194.12 | $11.10 | $20.08 |
| 2014 | $55.98 | $68.92 | $188.52 | $17.59 | $41.28 |
| 2015 | $72.30 | $78.72 | $109.65 | $18.84 | $33.58 |
| 2016 | $105.32 | $107.63 | $265.36 | $23.58 | $82.47 |
| 2017 | $271.74 | $194.94 | $607.61 | $28.01 | $124.10 |
| 2018 | $230.84 | $208.50 | $1,274.75 | $39.84 | $200.35 |
| 2019 | $225.17 | $215.04 | $1,259.37 | $44.02 | $164.77 |
| 2020 | $536.44 | $367.93 | $366.23 | $148.15 | $243.72 |
| 2021 | $400.67 | $306.52 | $2,113.79 | $89.52 | $639.11 |
| 2022 | $312.79 | $230.14 | $417.46 | $63.97 | $12.83 |
| 2023 | $312.49 | $231.02 | $250.34 | $71.13 | $66.28 |
| 2024 | $173.75 | $181.55 | $22.87 | $73.67 | $65.13 |
| 2025 | $189.02 | $191.59 | $25.04 | $77.32 | $50.32 |
AI valuation
Our deep-learning model estimates Align Technology, Inc.'s (ALGN) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $191.59
- Current price
- $178.91
- AI upside
- +7.09%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$90.73
-49.29% upside
Graham-Dodd
$77.32
-56.78% upside
Graham Formula
$50.32
-71.87% upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ALGN | Align Technology, Inc. | $178.91 | 13.64B | +7% | -49% | -57% | -72% | 33.42 | 3.39 | 3.40 | 15.94 | 6259.75 | 3.96 | 68.33% | 15.27% | 10.17% | 10.39% | 14.49% | 6.59% | 0.02 | — | 1.36 | 1.14 | -1.27 | 53.00% | 90.00% | -473.00% | 4.33% | 0.31 | 19.89% | 0.00% | 0.00% | 0.64% | 20.61 | 21.41 | 3.15 | 4.87 |
| BIO | Bio-Rad Laboratories, Inc… | $278.44 | 7.52B | +7% | -54% | +41% | -13% | 10.03 | 1.02 | 2.95 | 15.99 | — | 1.14 | 52.01% | 10.47% | 29.42% | 10.84% | 3.01% | 7.62% | 0.21 | 5.52 | 5.62 | 3.90 | 2.10 | -14264.00% | 65.00% | 4072.00% | 4.91% | 1.03 | 5.46% | 0.00% | 0.00% | 3.88% | 28.14 | 20.32 | 2.95 | 3.15 |
| BMRN | BioMarin Pharmaceutical I… | $61.73 | 11.86B | +37% | -52% | -36% | -40% | 32.84 | 1.88 | 3.56 | 18.32 | — | 2.02 | 77.13% | 16.56% | 10.83% | 5.94% | 7.50% | 4.79% | 0.10 | 48.95 | 5.21 | 3.25 | -1.25 | -1855.00% | 1287.00% | 5249.00% | 6.33% | 1.09 | 14.09% | 0.00% | 0.00% | 3.68% | 19.67 | 14.48 | 3.26 | 5.75 |
| ENSG | The Ensign Group, Inc. | $214.17 | 12.45B | -38% | +33% | -70% | -27% | 35.93 | 5.54 | 2.45 | 28.09 | 255.48 | 5.81 | 13.74% | 8.58% | 6.80% | 16.92% | 7.20% | 6.80% | 1.86 | 54.31 | 1.42 | 1.35 | 6.43 | 1406.00% | 1872.00% | 9620.00% | 3.00% | 0.63 | 8.15% | 0.12% | 4.20% | 0.29% | 36.77 | 43.03 | 3.15 | 4.02 |
| EXEL | Exelixis, Inc. | $44.06 | 11.81B | +59% | -51% | -50% | -3% | 14.24 | 5.16 | 4.80 | 11.13 | 24.57 | 5.31 | 96.39% | 37.59% | 33.73% | 35.53% | 55.80% | 27.02% | 0.08 | — | 3.56 | 3.32 | -0.34 | 5795.00% | 698.00% | 3322.00% | 7.58% | 2.18 | 64.97% | 0.00% | 0.00% | 11.04% | 11.76 | 12.15 | 4.42 | 12.01 |
| GMED | Globus Medical, Inc. | $95.46 | 12.89B | +11% | +76% | -55% | 0% | 23.57 | 2.77 | 4.31 | 16.77 | 5.58 | 5.30 | 67.41% | 16.33% | 18.30% | 12.29% | 10.63% | 10.19% | 0.03 | — | 4.26 | 2.48 | -0.56 | 42267.00% | 1665.00% | 4530.00% | 4.64% | 1.51 | 14.79% | 0.00% | 0.00% | 3.63% | 25.51 | 20.79 | 4.16 | 12.01 |
| HIMS | Hims & Hers Health, Inc. | $14.52 | 3.19B | +579% | +6,822% | -72% | +154% | 28.88 | 6.85 | 1.58 | 24.62 | — | 55.76 | 59.31% | 5.18% | 5.47% | 25.23% | 17.20% | 8.97% | 2.34 | — | 1.90 | 1.51 | 5.80 | -377.00% | 5900.00% | -6271.00% | 1.99% | 0.74 | 10.45% | 0.00% | 0.00% | 2.43% | 36.11 | 59.40 | 1.87 | 2.78 |
| PEN | Penumbra, Inc. | $344.39 | 13.51B | -36% | -28% | -84% | -67% | 74.97 | 9.33 | 9.49 | 59.99 | 6.49 | 10.62 | 67.14% | 13.48% | 12.66% | 13.78% | 13.14% | 10.58% | 0.15 | — | 6.64 | 2.06 | 0.15 | 115556.00% | 1750.00% | 1876.00% | 1.31% | 1.30 | 14.03% | 0.00% | 0.00% | 0.00% | 70.57 | 76.34 | 9.51 | 22.01 |
| QGEN | Qiagen N.V. | $49.80 | 10.26B | +6% | -52% | -77% | -45% | 23.90 | 2.69 | 4.86 | 14.93 | 5.47 | 14.69 | 61.79% | 24.90% | 20.33% | 11.57% | 10.79% | 7.09% | 0.44 | 15.65 | 3.90 | 2.93 | 1.14 | 43684.00% | 565.00% | -1049.00% | 4.46% | 1.28 | 10.85% | 0.53% | 12.80% | 1.82% | 20.58 | 23.63 | 5.12 | 3.92 |
| RVTY | Revvity, Inc. | $98.31 | 11.15B | +3% | -60% | -88% | -75% | 44.87 | 1.49 | 3.79 | 20.25 | — | -6.33 | 53.08% | 12.49% | 8.46% | 3.23% | 3.28% | 1.96% | 0.48 | 3.87 | 1.68 | 1.25 | 3.92 | -1369.00% | 367.00% | -617.00% | 4.70% | 0.44 | 5.17% | 0.30% | 13.60% | 7.89% | 37.63 | 26.40 | 4.70 | 1.74 |
About Align Technology, Inc.
Align Technology, Inc., a medical device company, designs, manufactures, and markets Invisalign clear aligners and iTero intraoral scanners and services for orthodontists and general practitioner dentists, and restorative and aesthetic dentistry. It operates in two segments, Clear Aligner; and Scanners and Services. The Clear Aligner segment consists of comprehensive products, including Invisalign comprehensive treatment that addresses the orthodontic needs of teenage patients, such as mandibular advancement, compliance indicators, and compensation for tooth eruption; and Invisalign First Phase I and Invisalign First Comprehensive Phase 2 package for younger patients generally between the ages of seven and ten years, which is a mixture of primary/baby and permanent teeth. This segment's non-comprehensive products comprise Invisalign moderate, lite and express packages, and Invisalign go; and non-case products include retention products, Invisalign training fees, and sales of ancillary products, such as cleaning material, and adjusting tools used by dental professionals during the course of treatment. The Scanners and Services segment offers iTero scanner, a single hardware platform with software options for restorative or orthodontic procedures; restorative software for general practitioner dentists, prosthodontists, periodontists, and oral surgeons; and software for orthodontists for digital records storage, orthodontic diagnosis, and for the fabrication of printed models and retainers. This segment also provides computer-aided design and computer-aided manufacturing services; ancillary products, such as disposable sleeves for the wand; iTero model and dies; third party scanners and digital scans; Invisalign outcome simulator, a chair-side and cloud-based application for the iTero scanner; Invisalign progress assessment tool; and TimeLapse technology, which allows doctors or practitioners to compare a patient's historic 3D scans to the present-day scan. The company sells its products in the United States, Switzerland, China, and internationally. Align Technology, Inc. was incorporated in 1997 and is headquartered in Tempe, Arizona.
- CEO
- Joseph Hogan
- Employees
- 21.2K
- Beta
- 1.83
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($90.73 ÷ $178.91) − 1 = -49.29% (DCF, example).